Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer

Table 2 Rates of tumor response attributable to abiraterone in the pre- and post-chemotherapy settings

	Pre-chemotherapyrate (95%CI)	Post-chemotherapyrate (95%CI)
Objective response	20.0% (16.9%-23.6%)	11.5% (9.5%-13.9%)b
PSA response	38.0% (34.0%-42.1%)	24.0% (21.2%-27.1%)b

^bP < 0.01, pre-chemotherapy vs post-chemotherapy rates. The response rate attributable to abiraterone = rate of abiraterone and prednisone minus that of placebo and prednisone.